StockUS listing USQTTBNASDAQHealthcareQuality Compounder

Q32 Bio Inc(QTTB) Stock Analysis | Healthcare

USD --+0.00%
Reward67High
Risk27Low
75%Data
Strong 60% profit margin
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 276.80M
Reward Ratingⓘ67 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ27 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on QTTB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Q32 Bio Inc?

, a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

AI Brief Pro

The brief on Q32 Bio Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Q32 Bio Inc?

, a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 276.80M, and a P/E ratio of 2.6x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (67)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap276.80M
P/E Ratio2.5694
Beta-0.111
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
316,706 shares
$75k
0
9-12months
231,578 shares
$109k
0